$130.5 M

HTGM Mkt cap, 20-Sep-2018

$9.1 M

HTG Molecular Diagnostics Revenue Q2, 2018
HTG Molecular Diagnostics Gross profit (Q2, 2018)6.5 M
HTG Molecular Diagnostics Gross profit margin (Q2, 2018), %71.5%
HTG Molecular Diagnostics Net income (Q2, 2018)-9.5 M
HTG Molecular Diagnostics EBIT (Q2, 2018)-9.3 M
HTG Molecular Diagnostics Cash, 30-Jun-20185.8 M

HTG Molecular Diagnostics Revenue

HTG Molecular Diagnostics revenue was $14.76 m in FY, 2017

Embed Graph

HTG Molecular Diagnostics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

4 m5.1 m14.8 m

Revenue growth, %

27%

Cost of goods sold

3.3 m4.1 m5 m

Gross profit

706.1 k996.8 k9.8 m

Gross profit Margin, %

17%19%66%

R&D expense

4.6 m7.9 m10 m

General and administrative expense

15 m17.4 m17.5 m

Operating expense total

19.6 m25.3 m27.5 m

EBIT

(18.9 m)(24.3 m)(17.7 m)

EBIT margin, %

(467%)(474%)(120%)

Interest expense

1.7 m1.9 m1.3 m

Interest income

85.9 k112.4 k73.2 k

Pre tax profit

(21.4 m)(26 m)(19 m)

Income tax expense

10.2 k10.1 k2.9 k

Net Income

(21.4 m)(26 m)(19 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

790.6 k1 m865.2 k1.9 m913.9 k1.4 m1.8 m4.2 m9.1 m

Cost of goods sold

834.9 k809 k843.5 k933 k1.1 m1.3 m1.2 m1.1 m2.6 m

Gross profit

(44.4 k)201.9 k21.8 k962.8 k(211.1 k)75.9 k523.9 k3 m6.5 m

Gross profit Margin, %

(6%)20%3%51%(23%)6%30%73%71%

R&D expense

953.2 k1.3 m2 m2.6 m1.9 m1.3 m1.6 m2.6 m5.3 m

General and administrative expense

3.7 m3.7 m4.7 m4.7 m3.9 m4.2 m4.4 m5.7 m10.4 m

Operating expense total

4.7 m5 m6.7 m7.3 m5.8 m5.5 m6 m8.2 m15.8 m

EBIT

(4.7 m)(4.8 m)(6.7 m)(6.4 m)(6.1 m)(5.4 m)(5.5 m)(5.2 m)(9.3 m)

EBIT margin, %

(598%)(477%)(770%)(336%)(663%)(396%)(313%)(126%)(102%)

Interest expense

476.1 k378.7 k392.5 k538.9 k490.8 k398.4 k350.1 k182.5 k415.8 k

Interest income

11.1 k37.8 k35.5 k31.1 k26.2 k12.1 k17.6 k133.2 k330.9 k

Pre tax profit

(6.5 m)(5.2 m)(7 m)(6.9 m)(6.5 m)(5.8 m)(5.8 m)(5.4 m)(9.5 m)

Income tax expense

3.4 k860 4.3 k280 860 3.5 k

Net Income

(6.5 m)(5.2 m)(7 m)(6.9 m)(6.5 m)(5.8 m)(5.8 m)(5.4 m)(9.5 m)

HTG Molecular Diagnostics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

3.3 m7.5 m10 m

Accounts Receivable

716.2 k1.4 m6.4 m

Current Assets

34.9 m15.1 m17.9 m

PP&E

1.9 m3.3 m3.3 m

Total Assets

39.4 m18.5 m21.3 m

Accounts Payable

724.8 k761.7 k2.4 m

Current Liabilities

6.3 m10 m13.3 m

Total Liabilities

24 m24.3 m

Additional Paid-in Capital

106.6 m110.1 m131.5 m

Retained Earnings

(89.6 m)(115.6 m)(134.6 m)

Total Equity

16.9 m(5.6 m)(3.1 m)

Financial Leverage

2.3 x-3.3 x-6.9 x

Quarterly

USDQ1, 2018Q2, 2018

Cash

20.5 m5.8 m

Accounts Receivable

2.8 m3.5 m

Current Assets

50.2 m46.1 m

PP&E

3.1 m2.9 m

Total Assets

53.3 m49 m

Accounts Payable

2.2 m1.3 m

Current Liabilities

5.1 m4.9 m

Total Liabilities

22.4 m21.8 m

Additional Paid-in Capital

170.9 m171.2 m

Retained Earnings

(139.9 m)(144 m)

Total Equity

31 m27.2 m

Financial Leverage

1.7 x1.8 x

HTG Molecular Diagnostics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(21.4 m)(26 m)(19 m)

Depreciation and Amortization

662.6 k1.5 m1.2 m

Accounts Receivable

40 k(661.2 k)(5 m)

Inventories

(746.2 k)(33.2 k)77.2 k

Accounts Payable

(312.3 k)10.1 k1.2 m

Cash From Operating Activities

(19.2 m)(22.2 m)(16.6 m)

Purchases of PP&E

(1.3 m)(1.9 m)(1 m)

Cash From Investing Activities

(32.2 m)24.4 m3.3 m

Cash From Financing Activities

51.1 m2 m15.8 m

Interest Paid

935 k1.1 m698.1 k

Income Taxes Paid

2 k

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(6.5 m)(5.2 m)(7 m)(6.9 m)(6.5 m)(5.8 m)

Accounts Receivable

852.3 k554.2 k696.8 k574.6 k1.9 m591.9 k1.2 m1.6 m

Accounts Payable

879 k1.2 m966.9 k2.2 m1.6 m1.1 m1.2 m1.3 m

HTG Molecular Diagnostics Ratios

USDY, 2018

Financial Leverage

1.8 x
Report incorrect company information